Skip header and navigation

1 records – page 1 of 1.

Adalimumab therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1207
Available Online
View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Alternate Title
Adalimumab therapy for IBD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Adalimumab (Humira) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1207
Less detail